Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of huCART-meso and VCN-01 in Pancreatic and Ovarian Cancer
NCT05057715Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Mar 2022
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of huCART-meso cells and zabilugene almadenorepvec in pancreatic adenocarcinoma (PDAC) and Serous Epithelial Ovarian Cancer (SOC) (5 arms), sponsored by University of Pennsylvania. Primary endpoints: Type, frequency, severity, and attribution of Adverse Events and Serious Adverse Events at 2 years, Occurrence of dose-limiting toxicities at 2 years and 3 more. Started Mar 2022; status: terminated.
02
Drugs
huCART-meso cellszabilugene almadenorepvec
03
Conditions
pancreatic adenocarcinoma (PDAC)Serous Epithelial Ovarian Cancer (SOC)
Beyond the preview
Go deeper on NCT05057715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057715.